Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Waidmann

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Cancer Research|August 5, 2015
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular CarcinomaChristian Schmithals, Verena Köberle, Hüdayi Korkusuz, et al.
Biochemical Pharmacology|October 17, 2017
Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSESabrina Khageh Hosseini, Stefanie Kolterer, Marlene Steiner, et al.
Plos One|November 9, 2011
Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinomaVerena Bihrer, Oliver Waidmann, Mireen Friedrich-Rust, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trialKlara Dorman, Stefan Boeck, Karel Caca, et al.
Ebiomedicine|June 18, 2024
Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in miceChristian Schmithals, Bianca Kakoschky, Dominic Denk, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|January 15, 2020
[Introduction of an interdisciplinary tumor board leads to improvement of treatment outcome of cholangiocarcinoma (bile duct cancer)]Mazen A Juratli, Konstantin Hofmann, Ümniye Balaban, et al.
Plos One|January 22, 2021
Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidatesPhilip G Ferstl, Natalie Filmann, Eva-Maria Heilgenthal, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|November 9, 2021
Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric CancerCaspar Franck, Nadja Zimmermann, Elisabetta Goni, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2019
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohortBernhard Scheiner, Martha M Kirstein, Florian Hucke, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Cancer Research|August 5, 2015
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular CarcinomaChristian Schmithals, Verena Köberle, Hüdayi Korkusuz, et al.
Biochemical Pharmacology|October 17, 2017
Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSESabrina Khageh Hosseini, Stefanie Kolterer, Marlene Steiner, et al.
Plos One|November 9, 2011
Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinomaVerena Bihrer, Oliver Waidmann, Mireen Friedrich-Rust, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trialKlara Dorman, Stefan Boeck, Karel Caca, et al.
Ebiomedicine|June 18, 2024
Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in miceChristian Schmithals, Bianca Kakoschky, Dominic Denk, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|January 15, 2020
[Introduction of an interdisciplinary tumor board leads to improvement of treatment outcome of cholangiocarcinoma (bile duct cancer)]Mazen A Juratli, Konstantin Hofmann, Ümniye Balaban, et al.
Plos One|January 22, 2021
Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidatesPhilip G Ferstl, Natalie Filmann, Eva-Maria Heilgenthal, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|November 9, 2021
Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric CancerCaspar Franck, Nadja Zimmermann, Elisabetta Goni, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2019
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohortBernhard Scheiner, Martha M Kirstein, Florian Hucke, et al.
Pageof 12